ESH CML/MPN 2025 | The potential impact of combination therapies on the landscape of myelofibrosis treatment

First, we hope that at some point we get a combination approved because so far we don’t have any combination approved. The development of navitoclax has been stopped. Pelabresib continues. We are very excited to wait for the final results of the XPORT-MF-034 trial with selinexor. And there is another trial that has already started, another combo for us first line, which combines ruxolitinib plus navtemadlin, but for suboptimal response patients, so it’s not from the start. Patients will receive rux and then they will be randomized between rux plus placebo and rux plus navtemadlin, and so this is a trial for more suboptimal response patients.

So how are these combos going to shape the future? We first hope that these trials are going to be positive, if they are positive, they reach their endpoints, and if they are approved by the different health authorities, they’re gonna change the first line of myelofibrosis because they have disease-modifying effects, they decrease for most of them, they decrease the bone marrow fibrosis, they reshape the microenvironment in the bone marrow, and they decrease the tumor burden. So we hope that in the long term, this will have an effect on patient survival because we know that patient survival depends on all these above parameters. So, they work better on the spleen volume, they work better on the tumor burden, they work better on the fibrosis, most of them have an impact on the erythropoiesis. So lots of benefits to using these combos. So they will reshape the first line, and the first line is going at some point to be a combo.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.